Natixis Precision Biosciences Inc Transaction History
Natixis
- $16 Billion
- Q4 2024
Shares
3 transactions
Others Institutions Holding DTIL
# of Institutions
7Shares Held
2.56MCall Options Held
0Put Options Held
0-
Oup Management Co., LLC1.12MShares$6.66 Million0.86% of portfolio
-
Chi Advisors LLC New York, NY607KShares$3.6 Million0.1% of portfolio
-
Jacob Asset Management Of New York LLC Hermosa Beach, CA390KShares$2.32 Million0.19% of portfolio
-
Tekla Capital Management LLC225KShares$1.33 Million0.0% of portfolio
-
Vericrest Private Wealth Newtown, PA155KShares$917,3350.3% of portfolio
About PRECISION BIOSCIENCES INC
- Ticker DTIL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 110,818,000
- Market Cap $657M
- Description
- Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...